Get the Stockscreener App
15.80
2.87%
-0.555
Vtv Therapeutics Inc stock is traded at $15.80, with a volume of 3,294.
It is down -2.87% in the last 24 hours and down -20.35% over the past month.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
See More
Previous Close:
$16.36
Open:
$15.876
24h Volume:
3,294
Relative Volume:
0.16
Market Cap:
$41.63M
Revenue:
$5.02M
Net Income/Loss:
$-18.31M
P/E Ratio:
-3.489
EPS:
-4.53
Net Cash Flow:
$-23.40M
1W Performance:
-10.53%
1M Performance:
-20.35%
6M Performance:
-0.94%
1Y Performance:
-33.15%
1-Day Range:
$15.54
$15.98
1-Week Range:
$15.54
$18.09
52-Week Range:
$12.12
$26.99
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Name
Vtv Therapeutics Inc
Sector
Industry
Phone
336-841-0300
Address
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
15.89 | 50.90M | 5.02M | -18.31M | -23.40M | -4.53 |
|
ONC
Beone Medicines Ltd Adr
|
245.77 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.42 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.81 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.38 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-30-19 | Initiated | H.C. Wainwright | Buy |
| Apr-10-18 | Downgrade | Stifel | Buy → Hold |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Initiated | Northland Capital | Outperform |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Sep-04-15 | Initiated | Canaccord Genuity | Buy |
| Aug-24-15 | Initiated | Piper Jaffray | Overweight |
| Aug-24-15 | Initiated | Stifel | Buy |
View All
Vtv Therapeutics Inc Stock (VTVT) Latest News
(VTVT) Technical Data - news.stocktradersdaily.com
vTv resumes Phase III oral T1D drug study - The Pharma Letter
vTv Therapeutics appoints new CFO amid Phase 3 trial By Investing.com - Investing.com South Africa
vTv Therapeutics Appoints New CFO Amidst Phase 3 Trial - TipRanks
vTv Therapeutics Appoints Michael Tung, M.D., MBA, As Chief Financial Officer - citybiz
VTv Therapeutics Names Michael Tung as Finance Chief - marketscreener.com
vTv Therapeutics (VTVT) Appoints New CFO | VTVT Stock News - GuruFocus
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Fina - GuruFocus
VTv Therapeutics Names Michael Tung CFO, Effective Immediately - Nasdaq
vTv Therapeutics appoints new CFO amid Phase 3 trial - Investing.com
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief - GlobeNewswire
vTv Therapeutics Advances First-in-Class Oral Type 1 Diabetes Drug as New CFO Joins - Stock Titan
VTv Therapeutics: Q1 Earnings Snapshot - Bluefield Daily Telegraph
How to Take Advantage of moves in (VTVT) - news.stocktradersdaily.com
vTv Therapeutics Highlights Cadisegliatin’s Potential for Diabetes - TipRanks
VTVT Advances Cadisegliatin Program with Phase 3 Study | VTVT St - GuruFocus
vTv Therapeutics advances type 1 diabetes trial By Investing.com - Investing.com South Africa
vTv Therapeutics Inc Reports Q1 2025 EPS of -$0.77, Beating Estimates; Net Loss at $5.1 Million - GuruFocus
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update - The Manila Times
vTv Therapeutics Accelerates Timeline for First-Ever Oral Type 1 Diabetes Drug as Phase 3 Trial Advances - Stock Titan
VTV Therapeutics Announces Reinitiation Of Screening In CATT1 Phase 3 Trial - marketscreener.com
vTv Therapeutics advances type 1 diabetes trial - Investing.com Australia
VTv Therapeutics Resumes Cadisegliatin Testing in Type 1 Diabetes - marketscreener.com
vTv Therapeutics (VTVT) Resumes Phase 3 Trial for Diabetes Treat - GuruFocus
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes | VTVT Stock New - GuruFocus
vTv Therapeutics (VTVT) Resumes Phase 3 Trial for Diabetes Treatment | VTVT Stock News - GuruFocus
vTv Therapeutics Announces Reinitiation of CATT1 Phase 3 Trial for Cadisegliatin, Shortens Duration to Expedite Topline Data Expected in 2026 - Nasdaq
vTv Therapeutics Announces Reinitiation of Screening in - GlobeNewswire
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes - Stock Titan
How the (VTVT) price action is used to our Advantage - news.stocktradersdaily.com
vTv Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $158,000 Holdings in vTv Therapeutics Inc. (NASDAQ:VTVT) - Defense World
vTv Therapeutics (VTVT) to Release Quarterly Earnings on Thursday - Defense World
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com - Defense World
vTv Therapeutics Appoints Barry Brown as Interim CFO - MSN
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at HC Wainwright - Defense World
Q1 Earnings Forecast for VTVT Issued By HC Wainwright - Defense World
HC Wainwright Initiates vTv Therapeutics With Buy Rating, $36 Price Target - MarketScreener
This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - Nasdaq
H.C. Wainwright sets $36 target for vTv Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright sets $36 target for vTv Therapeutics stock - Investing.com
(VTVT) Trading Advice - news.stocktradersdaily.com
vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com - Defense World
(VTVT) Trading Signals - news.stocktradersdaily.com
Vtv Therapeutics Inc Stock (VTVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):